PFE - Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy Interim Data Shows | Benzinga
ViiV Healthcare, majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:PFE) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial.
The data indicated that long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges.
Related Content: Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says.
During the randomized phase of the study, 146 participants received monthly LA-ART, and 148 continued ...